PROCEPT BioRobotics (PRCT) Competitors

PROCEPT BioRobotics (NASDAQ:PRCT) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

Is PRCT or ATRI more profitable?

Atrion has a net margin of 10.60% compared to PROCEPT BioRobotics' net margin of -66.12%. Atrion's return on equity of 7.75% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-66.12%	-41.35%	-27.92%
Atrion	10.60%	7.75%	7.12%

Which has stronger valuation & earnings, PRCT or ATRI?

Atrion has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$136.19M	25.51	-$105.90M	-$2.12	-31.87
Atrion	$176.67M	4.51	$19.41M	$10.64	42.54

Which has more risk and volatility, PRCT or ATRI?

PROCEPT BioRobotics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Does the MarketBeat Community prefer PRCT or ATRI?

Atrion received 101 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 62.22% of users gave PROCEPT BioRobotics an outperform vote while only 54.66% of users gave Atrion an outperform vote.

Company	Underperform	Outperform
PROCEPT BioRobotics	Outperform Votes 28 62.22%	Underperform Votes 17 37.78%
Atrion	Outperform Votes 129 54.66%	Underperform Votes 107 45.34%

Do analysts recommend PRCT or ATRI?

PROCEPT BioRobotics currently has a consensus target price of $61.20, suggesting a potential downside of 9.43%. Given PROCEPT BioRobotics' higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Atrion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Atrion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media favor PRCT or ATRI?

In the previous week, PROCEPT BioRobotics and PROCEPT BioRobotics both had 4 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.30 beat Atrion's score of 0.92 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atrion	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in PRCT or ATRI?

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 66.2% of Atrion shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 22.8% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Atrion beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.